This is a rare genetic condition where the body can't properly break down certain sugars. It causes a buildup of these sugars in the body, leading to various health problems. It's also known as Sly Disease.
Every report comes from a Lived member, sent anonymously.
Have you tried Enzyme Replacement Therapy for Sly Syndrome (MPS VII)?
Sly syndrome, also called mucopolysaccharidosis type VII (MPS VII), is a very rare inherited condition in which the body cannot properly break down certain long sugar chains called glycosaminoglycans (GAGs). Normally an enzyme called beta-glucuronidase helps recycle these molecules inside the cell's recycling compartments, known as lysosomes. When the enzyme is missing or works poorly, GAGs build up in tissues throughout the body, and the damage grows over time. The effects reach many organs: an enlarged liver and spleen, distinctive coarse facial features, a large head, hernias, clouding of the cornea (the clear front of the eye), hearing loss, frequent ear and airway infections, heart valve disease and skeletal changes that cause short stature, stiff joints and spine problems. Many children have developmental delay or intellectual disability, although some people at the milder end keep typical thinking skills. Severity varies more than in most conditions. In its most severe form, MPS VII causes hydrops fetalis, a buildup of fluid in the unborn baby, and many of these babies are stillborn or die soon after birth. Others first show signs in infancy or early childhood, and some with milder disease live into adolescence or adulthood.
MPS VII is caused by changes (variants) in the GUSB gene, which carries the instructions for beta-glucuronidase. It is inherited in an autosomal recessive pattern: a child is affected only after receiving a nonworking copy of the gene from each parent. Parents who each carry one copy usually have no symptoms, and each of their pregnancies has a 1 in 4 chance of being affected. Nothing a parent did during pregnancy causes the condition, and there are no lifestyle triggers. Which gene variants a person has, and how much enzyme activity remains, only partly predict how severe the disease will be.
Because MPS VII is so rare and shares features with other forms of mucopolysaccharidosis (especially types I and II), diagnosis usually starts when a specialist in genetic or metabolic disease recognizes the pattern of symptoms. A urine test can show high levels of GAGs, and a blood test measures beta-glucuronidase activity directly. Genetic testing of the GUSB gene confirms the diagnosis, which matters because some people have low enzyme readings without having the disease. MPS VII is one of the lysosomal disorders doctors look for when an unborn baby has unexplained hydrops fetalis. Once the family's gene variants are known, relatives can be tested to see whether they are carriers, and future pregnancies can be tested before birth. Genetic counseling helps families understand these options.
There is no cure, but treatment can slow some of the disease and ease many of its complications. The main specific treatment is vestronidase alfa (Mepsevii), an enzyme replacement therapy approved in the US for children and adults. It is a laboratory-made version of the missing enzyme, given as an infusion into a vein every two weeks, with each infusion taking about four hours. In the main trial, 12 people aged 8 to 25 had lower urine GAG levels after 24 weeks, and 10 of them improved in at least one measure such as walking distance, breathing capacity, shoulder movement, vision or motor skills. The enzyme does not reach the brain, so it is not known to help thinking or development, and it does not reverse damage already present before treatment starts. Mepsevii carries a boxed warning for anaphylaxis, a severe allergic reaction that has occurred as early as the first dose. For that reason, infusions are given where staff can treat a reaction, usually after an antihistamine, and people are watched for an hour afterward. A stem cell transplant from a donor can supply working enzyme from the new blood cells, including in the brain. It has been reported in only a handful of people with MPS VII, works best when done early before lasting nerve and bone damage, and carries serious risks such as graft rejection and graft-versus-host disease, in which donor cells attack the body. Gene therapy is being studied but is not yet available. Supportive care from a team of specialists does much of the day-to-day work: physical therapy and pain relief for stiff joints, surgery for hernias, hip or spine problems, hearing aids or ear tubes, corneal transplant for severe clouding, breathing support for airway disease, and heart medicines or valve replacement when the heart is affected. Learning and speech support help children with developmental delay.
MPS VII is lifelong and progressive, and its course depends heavily on severity. Some children have major health problems from birth, while others are mildly affected for years before skeletal, heart or breathing problems become more noticeable. Life expectancy ranges from infancy to adulthood, and heart disease and airway obstruction are major causes of death. Daily life often revolves around regular care. People on enzyme replacement spend part of a day at an infusion center every two weeks. Specialists commonly recommend check-ups about every six months, with yearly tests that may include heart ultrasound, breathing tests, a walking test, eye and hearing exams, and spine and brain imaging to catch problems such as fluid on the brain or a narrowing spinal canal before they cause lasting harm. Surgery and sedation need extra planning, because airway narrowing and breathing problems make anesthesia riskier than usual. Procedures are best done at centers experienced with mucopolysaccharidosis. Families also benefit from school support, mobility aids as joints stiffen, and connection with rare-disease organizations, since few local doctors will have seen MPS VII.
Ask about evaluation by a genetics or metabolic specialist when a child has a combination of features such as coarse facial features, an enlarged liver or spleen, hernias, cloudy corneas, stiff joints and slowing development, or when an unborn baby has unexplained hydrops. Families with an affected relative can ask about carrier and prenatal testing. Contact the care team promptly about new weakness, numbness or tingling in the arms or legs, a change in walking, or loss of bladder or bowel control, which can signal pressure on the spinal cord in the neck. Also call promptly about worsening breathing at night, new shortness of breath or swelling, or headaches, vomiting or a rapidly growing head in a young child. After a Mepsevii infusion, trouble breathing, bluish lips or skin, or feeling faint are signs of a severe allergic reaction and need emergency care right away by calling 911.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Sly Syndrome (MPS VII) is like, what's helped you, or ask the community a question.